Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. In the assessment of 12-month price targets, analysts unveil insights for Caribou Biosciences, presenting an average target of $10.25, a high estimate of $14.00, and a low estimate of $9.00. This current average has not chan…